Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma

Wu, Junhui; Wei, Jing; Chen, Haoliang; Dang, Yalong; Lei, Fang

doi:10.2174/0113894501286195231220094646

Cited by 2 publications

(1 citation statement)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brain NP (BNP) decreases glucose levels and improves insulin resistance in acute coronary syndrome [7]. (eNOS) expression and enhancing NO production [13]. Fasudil is the only clinically approved nonselective ROCK inhibitor used to decrease blood pressure [14].…”

Section: Metabolic Syndrome (Ms)mentioning

confidence: 99%

Fasudil, a Rho kinase inhibitor, attenuates cardiovascular changes in an experimental rat model of metabolic syndrome via modulation of PCSK9 and BNP.

Shamardl,

Nageeb,

Sadik

et al. 2024

Fayoum University Medical Journal

View full text Add to dashboard Cite

Introduction: Metabolic syndrome (MS) is an important cardiovascular risk factor. Rho-kinase (ROCK) is a novel cardiovascular therapeutic target and its activity is increased in patients with MS. Aim of the study:To investigate the impact of Fasudil, a Rho kinase inhibitor, on the Rho-ROCK pathway, nitric oxide (NO), brain natriuretic peptide (BNP) and cardiac PCSK9/LDL concentrations, and to explore its potential role in improving insulin resistance and cardiovascular abnormalities.Materials and Methods: 24 adults male Wistar albino rats were used and divided into 4 groups: Control, Fasudil1(10 mg/kg/day subcutaneously), Sucrose-fed (30% in drinking water), Sucrose + Fasudil group. daily for 3 weeks. Blood pressure and heart rate, serum biomarkers (ROCK1, BNP, NO, insulin, glucose and LDL-c), and cardiac PCSK-9 concentrations were assessed in addition to cardiac histopathology. Results:The data proved that sucrose + Fasudil treatment significantly ameliorated the levels of systolic blood pressure, glycemic indices, serum LDL, Rho kinase, NO, BNP and cardiac PCSK9 compared to the untreated sucrose group. Histology examination confirmed the positive impact of Fasudil on cardiac inflammation, fibrosis and tissue degeneration compared to the untreated. Conclusion:Fasudil has a cardioprotective effect with improved glycemic indices on sucrose-induced MS in rats. By its action not only on the RhoA/Rho kinase (ROCK) signaling pathway but also on BNP, NO, and cardiac PCSK9 modulation activity. The study provided a promise to use Fasudil clinically in MS beyond RhoA/ROCK inhibition.

show abstract

Section: Metabolic Syndrome (Ms)mentioning

confidence: 99%